Hetronifly (Serplulimab)

Hetronifly is being evaluated for use in several clinical settings where modulation of the immune checkpoint pathway may be beneficial.

• Investigational treatment for certain advanced solid tumours.
• Potential therapy for metastatic melanoma under clinical study.
• Under assessment for use in non‑small cell lung cancer.
• Explored as part of combination regimens with other immunotherapies.
• May be considered in research protocols for renal cell carcinoma.

• Serplulimab is a humanized monoclonal antibody that binds to the programmed death‑1 (PD‑1) receptor on activated T cells. By blocking the interaction between PD‑1 and its ligands (PD‑L1 and PD‑L2), the drug prevents inhibitory signaling that normally reduces T‑cell activity. This restoration of T‑cell function can enhance the immune system’s ability to recognize and attack abnormal cells, including malignant cells, within the body.

Adverse reactions to Hetronifly have been observed in clinical studies and post‑marketing reports.

Common

• Fatigue or weakness.
• Mild skin rash or pruritus.
• Nausea or decreased appetite.
• Diarrhoea or constipation.
• Low-grade fever.

Serious

• Immune‑mediated pneumonitis or interstitial lung disease.
• Severe hepatitis or liver enzyme elevation.
• Endocrine disorders such as hypothyroidism or adrenal insufficiency.
• Colitis or severe gastrointestinal inflammation.
• Infusion‑related reactions including hypotension or anaphylaxis.

Patients receiving Hetronifly should be monitored closely for immune‑related events and other safety concerns.

• Assess baseline organ function (liver, kidney, lung) before initiating therapy.
• Monitor for signs of autoimmune reactions, especially thyroid, adrenal, or pancreatic dysfunction.
• Observe for respiratory symptoms that could indicate pneumonitis.
• Conduct regular laboratory tests to detect hepatic or renal toxicity.
• Use caution in patients with a history of severe allergic reactions to biologic agents.
• Counsel patients to report new skin changes, gastrointestinal symptoms, or endocrine abnormalities promptly.

Hetronifly may interact with other agents that influence immune function or share metabolic pathways.

Avoid

• Concurrent use of other immune checkpoint inhibitors without specialist guidance.
• Live vaccines during treatment due to potential reduced efficacy and safety concerns.

Use with caution

• Systemic corticosteroids, which may diminish therapeutic effect.
• Immunosuppressive drugs such as azathioprine or methotrexate.
• Agents that prolong QT interval, given rare reports of cardiac events.
• Herbal supplements that modulate immune activity (e.g., echinacea, high‑dose vitamin C).